Acute Myeloid Leukemia Clinical Trial
— CPX-351 TA-SMPOfficial title:
A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia
The three classic myeloproliferative neoplasms (MPNs) include polycythemia Vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The natural history of these MPNs is the possible progression to acute myeloid leukemia (MPN-blast phase) at variable percentage depending the entity. Leukemic transformation of MPN occurs in 8% to 23% of primary myelofibrosis (PMF) patients in the first 10 years after diagnosis and in 4% to 8% of polycythemia vera (PV) and essential thrombocytosis (ET) patients within 18 years after diagnosis. The risk for leukemic transformation is increased by exposure to cytotoxic chemotherapy. The molecular pathogenesis of MPN-blast phase remains an area of active research. The prognosis of blast phase MPNs is very poor : approximately 50% of the patients are deemed eligible for intensive treatment (ie. conventional induction chemotherapy regimen with anthracyclines and cytarabine). The patients who are not fit for such intensive treatment approach due to age or comorbidities, are treated with Hypomethylating agents, low dose palliative chemotherapy, or supportive care. Nevertheless, there is a need for more effective and better tolerated treatment approaches in order to increase the response rate and hence, the transplant rates which should translate into improved survival. CPX-351 is a new formulation of cytarabine and daunorubicin encapsulated at a fixed 5:1 molar-ratio in liposomes that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy. Based on similarities between post-myelodysplastic syndrome (MDS) and post-MPN secondary AML in terms of disease resistance to chemotherapy, of fragile patient profile, The hypotheses made is that CPX-351 may improve the results of induction chemotherapy without increasing its toxicity and therefore may increase the proportion of patients who could benefit from an allogeneic Stem Cell Transplantation (SCT).
Status | Recruiting |
Enrollment | 42 |
Est. completion date | September 1, 2025 |
Est. primary completion date | July 21, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of newly secondary AML according to WHO 2016 classification following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis - Performance status 2 Eastern Cooperative Oncology Group (ECOG) grading. - Eligible for standard intensive chemotherapy - Absence of concomitant severe cardiovascular disease which would make intensive chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, reduced left ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram. Cardiac ejection fraction = 50% by echocardiography ou MUGA - Patient must have adequate organ function as indicated by the following laboratory values: - Renal - Serum creatinine: < 2 mg/dl OR calculated creatinine clearance*: = 30 mL/min by MDRD formula for patients with creatinine levels > 1.5 X institutional Upper Limit Normal (ULN) - Hepatic - Serum total bilirubin: = 2.5 X ULN OR direct bilirubin = ULN for patients with total bilirubin levels = 2 mg/dL unless Gilbert's Syndrome - Aspartate-Amino-Transferase (ASAT) and Alanine-Transaminase (ALAT): = 2.5 times ULN - Alkaline Phosphatase: = 5 X ULN, if > 2.5 X ULN, then liver fraction should be = 2.5 X ULN *Creatinine clearance should be calculated per institutional standard - Life expectancy should be of 12 weeks at least according to investigator evaluation - Female patients of childbearing potential must have a negative serum pregnancy test (ß-hCG) within 72 hours prior to receiving the first dose of CPX-351. Female patients who are not post-menopausal, free from menses for > 2 years or surgically sterilized, will have to use adequate barrier methods of contraception to prevent pregnancy or agree to abstain from becoming pregnant throughout the study, starting with Visit 1. - Male patients agree to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving CPX-351 and for 3 months post study. - Patients have the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study. Exclusion Criteria: - MPN/MDS mixed types - Prior therapy for AML transformation except for Hydroxyurea - Prior treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF), low-dose oral chemotherapy or Hypomethylating agents chemotherapy given in the chronic phase of MPN in the 30 days before inclusion, except for hydroxyurea. - Uncontrolled undercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance. - Active and uncontrolled infection - Current participation or participation in a study with an investigational compound or device within 30 days of initial dosing with study drug - Patients with acute promyelocytic leukemia. - Known human immunodeficiency virus (HIV) infection or HIV-related malignancy - Clinically active hepatitis B or hepatitis C infection. - Known allergy or hypersensitivity to any component of CPX-351. - Currently active second malignancy, other than non-melanoma skin cancer and in situ carcinoma of the cervix. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >3 years or are considered by their physician to be at less than 30% risk of relapse - Clinical evidence of Central Nervous System Leukemia. - Pregnancy or breastfeeding during the projected duration of the study. |
Country | Name | City | State |
---|---|---|---|
France | AMIENS - CHU Amiens Picardie | Amiens | |
France | ANGERS - CHU - Maladies du sang | Angers | |
France | AVIGNON - Centre Hospitalier | Avignon | |
France | BAYONNE - CH de la Côte Basque - Hématologie | Bayonne | |
France | AVICENNE - Centre de Recherche Clinique | Bobigny | |
France | BREST - Hôpital Morvan | Brest | |
France | CAEN - CHU Caen - IHBN | Caen | |
France | CLAMART - Hôpital d'Instruction des Armées de Percy | Clamart | |
France | Clermont-Ferrand - Chu Estaing | Clermont-Ferrand | |
France | CRETEIL - CHU Henri Mondor | Créteil | |
France | Grenoble - CHUGA - Hématologie Clinique | Grenoble | |
France | LILLE CHU - Hôpital Claude Huriez | Lille | |
France | LIMOGES - CHU Dupuytren 1 | Limoges | |
France | LYON-Centre Léon Bérard | Lyon | |
France | MARSEILLE - Institut Paoli-Calmettes | Marseille | |
France | MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique | Montpellier | |
France | NANTES - Hôpital Hôtel Dieu - Hématologie Clinique | Nantes | |
France | NICE - Centre Antoine Lacassagne | Nice | |
France | NICE - CHU - Hopital Archet 1 | Nice | |
France | NIMES - CHU Caremeau | Nîmes | |
France | ORLEANS - CHR - Hématologie | Orléans | |
France | Paris Saint Louis | Paris | |
France | Paris St Antoine | Paris | |
France | BORDEAUX - Hôpital Haut-Levêque | Pessac | |
France | LYON HCL - CH Lyon Sud | Pierre-Bénite | |
France | POITIERS - Hôpital La Milétrie - Hématologie Clinique | Poitiers | |
France | REIMS - Hôpital Robert Debré - Hématologie Clinique | Reims | |
France | RENNES - Hôpital Pontchaillou - Hématologie | Rennes | |
France | Strasbourg - Icans | Strasbourg | |
France | Toulouse - IUCT Oncopole - Service d'Hématologie | Toulouse | |
France | TOURS - Hôpital Bretonneau | Tours | |
France | NANCY - CHU de Brabois | Vandœuvre-lès-Nancy | |
France | VERSAILLES - Hôpital André Mignot | Versailles | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
French Innovative Leukemia Organisation | Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes |
France,
Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. — View Citation
Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887-4897. Blood Adv. 2020 Nov 24;4(22):5651. doi: 10.1182/bloodadvances.2020003711. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of CR/CRi after first induction therapy | Rate of CR/CRi according to ELN2017 criteria | After 28 to 42 days after one cycle of 5 days of CPX351 | |
Primary | Rate of CR/CRi after second induction therapy | Rate of CR/CRi according to ELN2017 criteria | If applicable, after 28 to 31 days after a second cycle of 3 days of CPX351 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |